Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series.

Abnormal movements occur rarely with selective serotonin reuptake inhibitors (SSRIs). This report describes four consecutive autistic children who developed extrapyramidal side effects (EPS) following SSRI exposure. Videotapes, physician notes, and parental interviews were used retrospectively to rate symptoms on the Extrapyramidal Symptom Rating Scale.

Once-daily high-dose pindolol for SSRI-refractory depression.

Selective serotonin reuptake inhibitor (SSRI) augmentation with the 5-HT1A antagonist pindolol has met with mixed results. Recent studies using positron emission tomography (PET) suggest that pindolol doses used in these studies were too low to effect 5-HT1A autoreceptor blockade. To test the hypothesis that a single higher dose of pindolol would effectively augment antidepressant responses in SSRI-refractory patients, nine subjects with major depression unresponsive to paroxetine 40 mg/day given for 2 months or more were randomized to AM pindolol 7.

Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385.

Adenosine plays a key role in the regulation of tissue oxygenation, neuronal firing, and neurotransmitter release. Four receptor subtypes have been identified and cloned: A(1), A(2A), A(2B), and A(3), although only A(1) and A(2A) receptors are prominent in rat brain. Much evidence now indicates that A(2A) receptors (A(2A)R) are highly enriched within striatal medium-sized spiny GABAergic neurons where they are closely associated with, and modulate, D(2)-dopaminergic receptors involved in motor control and reward behaviors.